HK1252813A1 - 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物 - Google Patents

用於治療社交障礙和藥物使用障礙的治療性化合物和組合物

Info

Publication number
HK1252813A1
HK1252813A1 HK18112118.2A HK18112118A HK1252813A1 HK 1252813 A1 HK1252813 A1 HK 1252813A1 HK 18112118 A HK18112118 A HK 18112118A HK 1252813 A1 HK1252813 A1 HK 1252813A1
Authority
HK
Hong Kong
Prior art keywords
disorders
compositions
therapeutic compounds
substance use
treating social
Prior art date
Application number
HK18112118.2A
Other languages
English (en)
Inventor
I‧S‧麥格雷戈
M‧卡修
M‧T‧博文
C‧希克斯
W‧約爾根森
Original Assignee
悉尼大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902659A external-priority patent/AU2015902659A0/en
Application filed by 悉尼大學 filed Critical 悉尼大學
Publication of HK1252813A1 publication Critical patent/HK1252813A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK18112118.2A 2015-07-06 2018-09-20 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物 HK1252813A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2015902659A AU2015902659A0 (en) 2015-07-06 Therapeutic compounds and compositions for treating social disorders and substance use disorders

Publications (1)

Publication Number Publication Date
HK1252813A1 true HK1252813A1 (zh) 2019-06-06

Family

ID=57684596

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112118.2A HK1252813A1 (zh) 2015-07-06 2018-09-20 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物

Country Status (19)

Country Link
US (3) US11033555B2 (zh)
EP (1) EP3328864B1 (zh)
JP (2) JP7089825B2 (zh)
KR (1) KR102686349B1 (zh)
CN (1) CN107922420B (zh)
AU (1) AU2016289271B2 (zh)
CA (1) CA2991236A1 (zh)
DK (1) DK3328864T3 (zh)
ES (1) ES2932194T3 (zh)
HK (1) HK1252813A1 (zh)
HU (1) HUE060496T2 (zh)
IL (1) IL256684B (zh)
MX (1) MX2017017171A (zh)
NZ (1) NZ738672A (zh)
PL (1) PL3328864T3 (zh)
PT (1) PT3328864T (zh)
RU (1) RU2715384C2 (zh)
SI (1) SI3328864T1 (zh)
WO (1) WO2017004674A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3328864T (pt) * 2015-07-06 2022-12-07 Kinoxis Therapeutics Pty Ltd Compostos e composições terapêuticos para tratamento de distúrbios sociais e distúrbios por uso de substâncias
AU2017377653B2 (en) * 2016-12-12 2022-04-21 Kinoxis Therapeutics Pty Ltd Non-peptide oxytocin receptor agonists
WO2020102857A1 (en) * 2018-11-23 2020-05-28 The University Of Sydney Methods for management of weight
CA3150103A1 (en) * 2019-09-06 2021-03-11 Kinoxis Therapeutics Pty Ltd OPIOID WITHDRAWAL TREATMENT
AU2021336662A1 (en) * 2020-09-07 2023-05-04 Kinoxis Therapeutics Pty Ltd Salts and crystals
WO2022126179A1 (en) * 2020-12-14 2022-06-23 The University Of Sydney Oxytocin receptor modulators
CA3211786A1 (en) * 2021-03-18 2022-09-22 Michael Thomas Bowen Methods of treatment
CN115677585B (zh) * 2022-10-31 2024-03-19 上海群力化工有限公司 一种甲醛吡唑衍生物的合成工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
EP1512687A1 (en) 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
WO2007050353A2 (en) 2005-10-24 2007-05-03 Wyeth Tricyclic compounds useful as oxytocin receptor agonists
GB0903493D0 (en) * 2009-02-27 2009-04-08 Vantia Ltd New compounds
PT3328864T (pt) 2015-07-06 2022-12-07 Kinoxis Therapeutics Pty Ltd Compostos e composições terapêuticos para tratamento de distúrbios sociais e distúrbios por uso de substâncias
CA3150103A1 (en) 2019-09-06 2021-03-11 Kinoxis Therapeutics Pty Ltd OPIOID WITHDRAWAL TREATMENT

Also Published As

Publication number Publication date
RU2018103873A3 (zh) 2019-09-04
AU2016289271A1 (en) 2018-01-25
JP7089825B2 (ja) 2022-06-23
CA2991236A1 (en) 2017-01-12
CN107922420B (zh) 2021-12-31
EP3328864B1 (en) 2022-09-07
NZ738672A (en) 2022-11-25
WO2017004674A1 (en) 2017-01-12
ES2932194T3 (es) 2023-01-16
HUE060496T2 (hu) 2023-03-28
US20190290658A1 (en) 2019-09-26
RU2018103873A (ru) 2019-08-06
MX2017017171A (es) 2018-04-30
US20240245706A1 (en) 2024-07-25
DK3328864T3 (da) 2022-12-05
IL256684B (en) 2022-06-01
JP2022130418A (ja) 2022-09-06
AU2016289271B2 (en) 2020-12-03
EP3328864A4 (en) 2019-01-09
BR112018000059A2 (pt) 2018-09-04
RU2715384C2 (ru) 2020-02-27
IL256684A (en) 2018-03-29
JP2018525351A (ja) 2018-09-06
SI3328864T1 (sl) 2023-02-28
US20220362261A1 (en) 2022-11-17
JP7490018B2 (ja) 2024-05-24
PL3328864T3 (pl) 2023-02-27
US11033555B2 (en) 2021-06-15
KR102686349B1 (ko) 2024-07-17
KR20180023992A (ko) 2018-03-07
CN107922420A (zh) 2018-04-17
PT3328864T (pt) 2022-12-07
US11890287B2 (en) 2024-02-06
EP3328864A1 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
IL251066B (en) Preparations and methods for the treatment of metabolic disorders
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
SG11201705093UA (en) Composition for treating il-6-related diseases
HK1252813A1 (zh) 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
HK1259372A1 (zh) 治療化合物、其組合物及使用方法
HK1256721A1 (zh) 用於治療眼部病症的化合物和組合物
ZA201807653B (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
HK1251009B (zh) 用於治療癌症的治療組合物
HK1247789A1 (zh) 用於治療水腫的組合物和方法
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
HK1232128A1 (zh) 用於預防或治療皮疹的藥物組合物
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
GB201612043D0 (en) Composition for treatment of disorders
HK1248130A1 (zh) 用於治療疼痛的組合物
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
HK1258765A1 (zh) 治療性化合物、組合物和它們的使用方法
IL249440B (en) Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases
GB201513543D0 (en) Compositions for use in the treatment of diabetes
AU2015902659A0 (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes
SG10201400824YA (en) Therapeutic Methods And Compositions For Treating Diabetes Utilizing Diterpenoid Compounds
HUE056121T2 (hu) Kompozíció UV-B terápia hatékonyságának növelésére, eljárás annak elõállítására, és alkalmazása